Tocilizumab
Anti-IL-6 receptor monoclonal antibody
- Response rate
- Case reports of efficacy
- Onset
- Weeks
- Route
- IV 8mg/kg every 4 weeks or SC
- Line
- Alternative
- IgM effect
- N/A
Evidence summary
IL-6 is elevated in TRAPS and drives SAA production. Case reports show tocilizumab can control disease when both etanercept and anakinra/canakinumab fail. First reported by Lane et al. 2011 in a patient refractory to prior biologics. Considered for refractory cases, particularly where SAA remains elevated.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-6 | Pro-inflammatory cytokine — acute phase driver | Elevated | moderate |